The aim of this study was to investigate the late effects of ABMT on the immune system with regard to protective humoral immunity against common antigens and responses to recall antigens (vaccines). The vaccines were given according to EBMT guidelines from 1995. The protocol included 35 patients with malignant lymphoma in CR 4-10 years after ABMT, and 35 controls. The results show that prior to ABMT the proportion of patients with protective immunity against poliomyelitis, tetanus and diphtheria was similar to that of controls. At study entry 4-10 years after ABMT, the proportion of patients with protective immunity against poliomyelitis and diphtheria was reduced, while all patients maintained protection against tetanus. A significant decrease in geometric mean antibody concentrations or titres was observed against all three antigens during this period. Serum levels of antibodies against different pneumococcal serotypes were lower in the patients than in the controls prior to vaccination. The responses to pneumococcal vaccination, which is considered to be a T cellindependent vaccine, were studied. Unlike controls, a minority of patients achieved protective levels of antibodies after a single vaccination. Despite persistent levels of protective antibodies in many patients post ABMT, secondary booster responses after one vaccination with T cell-dependent vaccines (tetanus, diphtheria and polio) were absent. In conclusion, this study shows that post ABMT, a full re-vaccination program was necessary to mount responses comparable to those observed after a single vaccination in controls. Bone Marrow Transplantation (2001) 28, 681-687.
Myeloablative therapies supported by autologous stem cell transplantation have proven to be effective treatments for certain haematological malignancies including relapsed non-Hodgkin's lymphoma, 1 relapsed Hodgkin's disease, 2 multiple myeloma 3 and acute myelogenous leukemia. 4 Reconstitution of lymphoid and other immune effector cells may take months to years. [5] [6] [7] There are increasing numbers of long-term survivors who have undergone myeloablative therapies and thus knowledge about late effects on the immune system is accumulating. Studies have shown that a majority of recipients of allogeneic bone marrow transplants lose protective immunity against, eg tetanus and poliomyelitis, over time. 8, 9 The situation in recipients of autologous bone marrow transplants is less well studied, particularly in long-term survivors.
In 1995 The Infectious Diseases Working Party of the EBMT published recommendations for re-immunisation in patients who had undergone allogeneic or autologous bone marrow transplantation 10 and these guidelines were revised in 1999. 11 The CDC (Centers for Disease Control and Prevention) published their latest recommendations in 2000. 12 According to the EBMTs 1995 guidelines, a full vaccination program against poliomyelitis, diphtheria and tetanus is strongly recommended post ABMT for all patients. Vaccinations against influenza, Haemophilus influenza type B and hepatitis B are recommended in certain subgroups of patients, while vaccination against pneumococci, measles, rubella or mumps may be given on an individual basis. In a previous publication we investigated the recovery and function of lymphoid cell subsets in this same population of lymphoma patients 4-10 years after ABMT. 13 We found lower numbers of CD4 + T lymphocytes, particularly CD4 + CD45RA + (naive) cells as well as differences in T cell cytokine production profiles upon stimulation with mitogens compared with controls. The aims of the present study were (1) to determine if there were changes in humoral immunity against viral and bacterial antigens several years after ABMT and (2) to study the function of the immune system by investigating serological responses to the vaccines recommended in the 1995 EBMT guidelines in lymphoma patients.
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Materials and methods
Patients and controls
All patients who received ABMT for malignant lymphoma at the Norwegian Radium Hospital in Norway from 1987 until 1993 and still were in CR were invited to participate in this study. Thirty-five patients out of 46 consented to participate. The patient population used for this study has been described in detail elsewhere. 13 The median age of the patients at the start of the study was 39.5 years (18-59 years) and the median time since ABMT was 5 years (4-10 years). Healthy blood donors (median age 39 years, range 18-60) were used as controls. Patient characteristics are summarised in Table 1 .
Childhood immunisation programs against tetanus, diphtheria and polio were launched in Norway during the 1950s. Most of our patients and controls have been vaccinated according to recommendations from the Norwegian Health Authorities. Some of the older participants in our study may have been exposed to different antigens by natural or subclinical infection. Thirty-five patients and 35 controls were vaccinated once. Thirty-three patients completed a full vaccination program according to the EBMT's guidelines from 1995, 10 except that our patients were vaccinated 4-10 years post ABMT, while EBMT recommend start of revaccination 1 year post therapy.
Vaccination scheme
Initially, all patients and controls received one combined vaccine against tetanus and diphtheria (SBL Vaccine AB, Stockholm, Sweden), and one vaccination against pneumococcal disease (Pneumovax, Pasteur Merieux MSD, Copen- Table 2 .
Serological analysis
Serum samples prior to ABMT were available from all patients who completed the full vaccination program. In addition, samples were drawn from patients and controls at study entry in 1997. Samples were also obtained prior to and 4 weeks after each vaccination. Specific IgG antibodies to tetanus toxoid were measured by an ELISA technique.
14 The assay's sensitivity limit was 0.1 IU/ml and antibody levels above this limit were considered protective for tetanus. Antibodies against diphtheria toxin were examined using a toxin-neutralising assay based on Vero cells in micro-culture. 15, 16 According to international guidelines, values у0.1 IU/ml were regarded as long-term protective for diphtheria, values from 0.01 to 0.1 IU/ml were regarded as relative or short-term protective and values Ͻ0.01 IU/ml were not considered protective. 17 Antibody titres against poliovirus (PV) types 1, 2 and 3 respectively, were measured by a microculture neutralisation assay, using Vero cells as an indicator system. 18 For each type of PV antibody titre у10 was regarded protective. 19 IgG antibodies to pneumococcal serotypes 4, 6B, 14, 18C and 19 F separately and to the 23-valent combined pneumococcal vaccine, were measured by an ELISA technique. 20 The levels of typespecific IgG antibodies was calculated using a pneumococcal reference serum 89SF (kindly supplied by Dr Carl E Frasch, Center for Biologics Evaluation and Research, Rockville, MD, USA). There is no defined protective level of pneumococcal antibodies, but 0.1-3.5 g/ml of type-specific antibodies have been protective in animal studies. 21 According to guidelines from The National Institute of Public Health in Oslo, IgG levels Ͼ1 g/ml were regarded as protective against infection with each serotype. The level of antibodies against all 23 serotypes combined in the Pneumovax vaccine was given in arbitrary units (U/ml) and no protective level is defined.
Tuberculin testing
A standard Pirquet's test with PPD (purified protein derivate) was used to test for delayed type hypersensitivity. 
Statistics
Statistical analyses were performed using SPSS 9.0 for Windows and Excel 97. Antibody concentrations were transformed into logarithms for the calculations of geometric mean antibody concentrations (GMC) or geometric mean antibody titres (GMT). Antibody results to poliovirus below the detection limits of the assays were assigned values of one half of this limit. Comparisons of antibody concentrations or titres between independent groups were performed using the Mann-Whitney U test. Paired analyses with related samples were done using the Wilcoxon sign rank sum test. The Pearson chi-square test, Fisher's exact test or McNemars test were used when appropriate, to compare categorical variables. Multiple linear regression was used to find predictors for serological response to vaccination. Data are given as median and ranges if not otherwise stated. P values are two-sided and considered significant when Ͻ0.05.
The study was recommended by the Regional Ethics Committee and participants signed written informed consents.
Results
Vaccination status
Six of the 35 patients (17%) had received one or more of the following vaccinations after ABMT and prior to our study: pneumococcal disease (3), tetanus (3), diphtheria (3) and poliomyelitis (2) . Among the 35 controls four (11%) had received one or more vaccinations during the last 5 years: tetanus (3), diphtheria (2) and poliomyelitis (4) . The pneumococcal vaccines were given to the cancer patients as protection for pneumonia. The other vaccines were probably given in order to increase protection when travelling outside of Europe, or in connection with wounds as prevention against tetanus.
Antibody status prior to ABMT and at study start 4-10 years later
Prior to ABMT the proportion of patients with protective immunity against tetanus, diphtheria and poliomyelitis were similar to controls at the beginning of the study (Figure 1) . From ABMT until the study started all patients maintained immunity to tetanus, even though there was a reduction in the GMC to tetanus toxoid in this period from 0.6 to 0.3 IU/ml (P Ͻ 0.001, Figure 2 ). For diphtheria, 19 patients (59%) had long-term protective antibody levels, seven (22%) had short-term protection, and six (19%) were not protected prior to ABMT. At study entry the corresponding figures were 12 patients (36%), 11 patients (32%) and 11 patients (32%) respectively. A decline in the GMC to diphtheria toxoid from 0.14 to 0.04 IU/ml (P Ͻ 0.005, Figure 3 ) was observed over this time period. Regarding poliomyelitis, 24 patients (77%) had protective antibody titres to all types of poliovirus (PV) before ABMT, whereas 17 patients (59%) maintained immunity at study start. The GMTs to all types of poliovirus decreased during follow-up, PV1 from 33.5 to 22.5 (P = 0.001), PV from 24.5 to 14.9 (P Ͻ 0.001) and PV3 from 25.6 to 16.9 (P = 0.002, Figure 4 ). In contrast to the other antigens tested, the GMC to pneumococcal serotypes 4, 6B and Pneumovax were lower in patients also prior to ABMT compared with controls (P Ͻ 0.05). At study start the GMC to all serotypes (4, 6B, 14,18,19F and Pneumovax) were lower in patients (P Ͻ 0.002, Table 3 ).
Antibody responses to vaccination
A single vaccination against tetanus led to a minor change in the GMC in patients from 0.3 to 0.4 IU/ml (P = 0.2), whereas the GMC increased from 0.5 to 2.3 IU/ml in controls (P Ͻ 0.001). After three immunisations a rise in the Bone Marrow Transplantation GMC to 1.8 IU/ml was observed in patients (P Ͻ 0.001, Figure 2 ). One vaccination against diphtheria also failed to induce a significant increase in levels of specific antibodies. The GMC to diphtheria increased from 0.04 to 0.06 IU/ml in patients (P = 0.2) and from 0.13 to 1.39 IU/ml in controls (P Ͻ 0.001). The numbers of patients who had long-term protection increased from 12 (36%) to 14 (41%), while corresponding figures in controls were 20 (59%) and 31 (91%), respectively. After three vaccinations, all patients obtained long-term protection against diphtheria and the GMC increased to 1.60 IU/ml (P Ͻ 0.001, Figure 3 ). Values represent geometric mean antibody concentrations and ranges, g/ml for the specific serotypes and U/ml for Pneumovax.
Regarding poliovirus, there was little change in the GMTs to PV1 (from 22.5 to 22.1), PV2 (no change) or PV3 (from 16.9 to 20.5) in patients following a single vaccination. After a full vaccination program there was a significant rise in serum levels to all PV types (P Ͻ 0.001, Figure 4) , and all except one patient achieved protective levels. The controls were not vaccinated against poliomyelitis.
In contrast, for all five serotypes tested (4, 6B, 14, 18, 19F) and to the total 23-valent vaccine, we observed a significant increase in GMC both in patients and controls after one vaccination with Pneumovax (P Ͻ 0.05, Table 3 ). However, the responses in the control group were generally stronger and unlike the control group, very few patients actually achieved protective serum levels (Table 4) .
Delayed type hypersensitivity testing
Responses to the standard tuberculin test (Pirquet's test) at study start showed that 28 of 32 (88%) patients tested were negative compared to only four of 28 (14%) controls. We do not have information about tuberculin status in patients before ABMT and they were not tested pre-ABMT. Vaccination against tuberculosis is, however, performed in most Norwegians, according to recommendations from the Norwegian Health Authorities.
Predictors for response to vaccination
We could not find any predictors for responses to diphtheria, tetanus or pneumococcal vaccines in patients, including age at study start, years since ABMT or numbers of CD4 + CD45RA + T cells (not shown). This finding was in contrast to the control group where age at study start was the single predictor for responses to diphtheria and tetanus vaccines (P Ͻ 0.05), but not to the pneumococcal vaccination (not shown). We tried to determine whether subtypes of lymphoma, tumour burden, the amount of prior chemotherapy or the purging of the graft influenced the vaccination response, but the groups were too small to consider regression analyses.
Discussion
Previous studies have provided evidence for loss of acquired immunity in patients after ABMT as well as BMT, indicating a need for revaccination. 8, 9, [22] [23] [24] Based on these reports recommendations for a revaccination program were launched in 1995 (and revised in 1999) by The Inectious Diseases Working Party of the EBMT. In healthy individuals there is also a continuing decrease in antibody levels against poliovirus, 25 tetanus 26 and diphtheria toxoid 27, 28 over time. Like controls, most patients in our study had protective levels of antibodies to the vaccine antigens prior to ABMT, in spite of the fact that all had received one or more chemotherapy regimens, with or without radiotherapy. During follow-up after ABMT, there was a significant decline in the GMC or GMT against all antigens tested for in the patient group. In a study by Pauksen and co-workers, 22 26% of patients were unprotected against at least one type of poliovirus (PV) 1 year after ABMT as compared to 8% before ABMT. Two to 3 years of further follow-up resulted in only a few more patients becoming seronegative. Another study after allogeneic transplantation showed that all patients lost immunity over time. 9 Twenty-three percent of our patients lacked protective immunity to at least one PV type before ABMT. Four to 10 years later an additional 18% of patients had lost protection. Our data support the observation made by Pauksen et al suggesting that the most rapid decline in antibody levels may occur during the first year after ABMT.
Hammarstrøm and colleagues 23 found that 58% of patients undergoing ABMT had protective antibody levels to tetanus prior to ABMT, compared to 29% 1 year after transplantation. In BMT patients the loss was even more pronounced. 8 Unlike Hammarstrøm et al, we found all patients in our study to be protected both before ABMT and also 4 to 10 years later. As with the other antigens tested, the loss of protection against diphtheria seems less pronounced after ABMT compared with BMT. 24, 29 In our study 81% of the patients were protected before transplantation compared with 68% post ABMT. The differences between ABMT and BMT with regard to immune status post transplantation may be explained by the continuous use of immunosuppressants in BMT patients post transplantation and by GVHD, both of which probably influence the survival of antibody producing cells. We conclude that there is a decline in the levels of specific antibodies after ABMT, more than would be expected in a healthy population over time. However, a high proportion of patients Bone Marrow Transplantation maintain protective levels of antibodies with a 4 to 10 years follow-up.
The most striking finding in the present study was the lack of response upon the first revaccination in patients. We expected a booster response to occur, since most patients had protective levels of antibodies in serum. No significant increase in antibody levels was found, suggesting that even a primary immune response was absent. Ljungman and colleagues 8 made a similar observation regarding antibody responses towards tetanus toxoid in BMT patients 1 year post BMT. The EBMT guidelines recommend start of revaccination at 1 year after transplantation. Lack of booster responses in our patients 4 to 10 years after ABMT indicates that postponing start of revaccination beyond 1 year might not be favourable.
The impaired responses upon the first vaccination may be caused by 'deficiencies' in T and/ or B lymphocytes. Our data from a previous report in the same patient cohort, 13 showed that abnormalities in the T cell subsets with reduced numbers of CD4 + cells persisted 4 to 10 years after ABMT. The CD4 + CD45RO + subset, which is considered to represent the memory cell compartment, was over-represented compared to the naive CD4 + CD45RA + cells. Similar findings have been made in the allogeneic setting, and that the CD4CD45RO + cells represent a limited repertoire post BMT. 30 Roux and colleagues 31 recently published data on T cell responses to vaccination with tetanus toxoid in patients post BMT and showed that higher levels of CD4 + CD45RA + cells predicted better responses. We could not find such a correlation in the patients post ABMT, but unlike Roux et al, we investigated humoral responses. There are differences in immune reconstitution between allogeneic and autologous transplantation which makes it difficult to directly compare the findings from Roux et al with our results.
ABMT results in alterations in thymic re-education and has been shown to induce peripheral tolerance. 32 It is, however, not likely that peripheral tolerance involving the CD4 +
CD45RA
+ compartment would explain the impaired primary response observed, since repeated identical vaccinations did lead to a significant increase in levels of specific antibodies. The severe reduction in CD4 + CD45RA + (naive) cells would rather indicate a low frequency of precursors, as a cause. The CD4
+ (memory) compartment, which would have been expected to help mount booster responses, dominates the CD4 + T cell subgroup in our patients. 13 Defects in the CD4 + CD45RO + subgroup could involve depletion of specific memory cells or altered function. The absence of response in most patients to a recall antigen (tuberculin) by delayed hypersensitivity testing supports the notion that T cell memory is impaired. B lymphocytes may also play an important role regarding unresponsiveness upon revaccination. It is unlikely that a lack of precursors would be a problem, since we have found that this patient population have normal B cell counts. 13 Eradication of specific memory B cells might occur after ABMT, but the absence of markers for these cells makes it difficult to investigate this. The majority of the patients in our study had advanced disease at diagnosis and/or relapse, and had received extensive chemotherapy prior to transplantation. We cannot rule out the possibility that this could have a negative impact on the vaccination response. In conclusion, despite a very low response to the first vaccination, almost all patients achieved satisfactory immune responses after completing a full vaccination program indicating an adequate T and B cell response to repeated antigen stimulation.
One may speculate how antibody levels can persist many years post ABMT when the vaccination data indicated the loss of immunological memory. The half-life of IgG is less than 21 days in humans. 33 Previous studies have suggested that long-term antibody responses are maintained by antigen-driven continuous differentiation of memory B cells into antibody secreting short-lived plasma cells. [34] [35] [36] [37] More recent publications by Slifka et al 38 and Mantz et al 39 provide strong evidence that plasma cells live much longer and are responsible for prolonged antibody levels independent of memory B cells in mice. Our results support the findings of Slifka and Mantz.
The response to T cell-independent vaccination against pneumococcal disease did not differ between patients and controls. However, serum antibodies did not reach protective levels in most patients, probably due to much lower antibody concentrations prior to vaccination compared with controls. Our results show that the regular pneumococcal polysaccharide vaccine did not induce protective immunity in most patients who had undergone ABMT.
In conclusion, in spite of a relative loss of humoral immunity in patients 4 to 10 years after ABMT, the majority of patients maintained protective levels of specific antibodies against the antigens tested. The first revaccination did not induce a booster response, or even a primary response. Furthermore, the T cell-independent pneumococcal polysaccaride vaccine may not be suitable for patients who have undergone ABMT. In order to achieve adequate protection against poliovirus, tetanus and diphtheria toxoid post ABMT, a full vaccination program according to the EBMT guidelines is recommended.
